Premium
Hematologic Response to Vorinostat Treatment in Relapsed Myeloid Leukemia of Down Syndrome
Author(s) -
Scheer Carina,
Kratz Christian,
Witt Olaf,
Creutzig Ursula,
Reinhardt Dirk,
Klusmann JanHenning
Publication year - 2016
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26062
Subject(s) - vorinostat , medicine , myeloid leukemia , histone deacetylase inhibitor , myeloid , leukemia , oncology , hematopoietic stem cell transplantation , histone deacetylase , chemotherapy , transplantation , pharmacology , histone , biochemistry , chemistry , gene
Children with Down syndrome are at high risk to develop myeloid leukemia (ML‐DS). Despite their excellent prognosis, children with ML‐DS particularly suffer from severe therapy‐related toxicities and for relapsed ML‐DS the cure rates are very poor. Here we report the clinical course of one child with ML‐DS treated with the histone deacetylase (HDAC) inhibitor vorinostat (suberoylanilide hydroxamic acid) after second relapse. The child had previously received conventional chemotherapy and stem cell transplantation, yet showed a remarkable clinical and hematologic response. Thus, HDAC inhibitor may represent an effective class of drugs for the treatment of ML‐DS.